^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DDX11-AS1 overexpression

    i
    Other names: DDX11-AS1, DDX11 Antisense RNA 1, CONCR, SCAT4, DDX11 Antisense RNA 1 (Non-Protein Coding), S-Phase Cancer-Associated Transcript 4, Cohesion Regulator Noncoding RNA, NONHSAG010798.2, HSALNG0090163, DDX11-AS1
    Entrez ID:
    100506660
    over3years
    LncRNA DDX11-AS1 Promotes Chemoresistance through LIN28A-Mediated ATG12 mRNA Stabilization in Breast Cancer. (PubMed, Pharmacology)
    This study clarifies the role of DDX11-AS1 in breast cancer chemoresistance and revealed a new mechanism, that is, interacting with LIN28A to stabilize ATG7 and ATG12 and jointly promote chemorefractory. These findings warrant further in vivo investigations to study DDX11-AS1 as a potential target to overcome chemoresistance.
    Journal
    |
    DDX11-AS1 (DDX11 Antisense RNA 1) • ATG12 (Autophagy Related 12) • ATG7 (Autophagy Related 7)
    |
    DDX11-AS1 overexpression
    |
    paclitaxel • doxorubicin hydrochloride • oxaliplatin
    over3years
    The Clinical Value of Long Noncoding RNA DDX11-AS1 as a Biomarker for the Diagnosis and Prognosis of Hepatocellular Carcinoma. (PubMed, J Oncol)
    Multivariate survival analysis verified that DDX11-AS1 expression level was an independent predictor for HCC patients. Overall, DDX11-AS1 may serve as a tumor promotor during HCC progression, and its high level may be a potential marker for HCC patients.
    Journal
    |
    DDX11-AS1 (DDX11 Antisense RNA 1)
    |
    DDX11-AS1 overexpression